CureVac (NASDAQ:CVAC) Trading Down 6.1% – Time to Sell?

CureVac (NASDAQ:CVAC)’s stock price traded down 6.1% during trading on Wednesday . The stock traded as low as $3.27 and last traded at $3.31. 525,492 shares traded hands during trading, a decline of 47% from the average session volume of 990,520 shares. The stock had previously closed at $3.52.

Analyst Upgrades and Downgrades

Separately, JMP Securities reissued a “market outperform” rating and set a $16.00 price objective on shares of CureVac in a report on Friday, February 14th.

CureVac Stock Down 6.5 %

The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The business’s 50-day simple moving average is $3.63 and its 200-day simple moving average is $3.21. The company has a market capitalization of $736.57 million, a PE ratio of 5.98 and a beta of 2.51.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Barclays PLC acquired a new stake in CureVac during the 3rd quarter worth about $67,000. Public Employees Retirement System of Ohio purchased a new position in CureVac during the third quarter valued at approximately $91,000. Jane Street Group LLC lifted its holdings in CureVac by 239.0% in the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in CureVac by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock worth $127,000 after purchasing an additional 16,792 shares in the last quarter. Finally, Signaturefd LLC lifted its stake in shares of CureVac by 26.9% in the 3rd quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock valued at $82,000 after purchasing an additional 5,927 shares during the period. Hedge funds and other institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.